307,309 results match your criteria Leukemias


Allogeneic Hematopoietic Cell Transplantation Provides No Benefit for Patients With Hypodiploid Acute Lymphoblastic Leukemia.

Authors:
Michael J Burke

J Clin Oncol 2019 Feb 22:JCO1900143. Epub 2019 Feb 22.

1 Medical College of Wisconsin, Milwaukee, WI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.00143DOI Listing
February 2019

Cancer risk in oil refinery workers: a pooled mortality study in Italy.

Med Lav 2019 Feb 22;110(1):3-10. Epub 2019 Feb 22.

Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano.

Background: Oil refinery workers are exposed to several well-established carcinogens and working in this type of industry has been classified by IARC as probable carcinogen to humans (Group 2A).

Objectives: To examine the mortality experience of workers employed in four Italian oil refineries.

Methods: The cohort included 5112 male workers ever employed between 1949 and 2011. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23749/mdl.v110i1.7842DOI Listing
February 2019

Should Watson Be Consulted for a Second Opinion?

Authors:
David D Luxton

AMA J Ethics 2019 Feb 1;21(2):E131-137. Epub 2019 Feb 1.

An affiliate associate professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle.

This article discusses ethical responsibility and legal liability issues regarding use of IBM Watson for clinical decision making. In a case, a patient presents with symptoms of leukemia. Benefits and limitations of using Watson or other intelligent clinical decision-making tools are considered, along with precautions that should be taken before consulting artificially intelligent systems. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/amajethics.2019.131DOI Listing
February 2019

CAR T cells generated using Sleeping Beauty transposon vectors and expanded with an EBV-transformed lymphoblastoid cell line (LCL) display antitumor activity in vitro and in vivo.

Hum Gene Ther 2019 Feb 22. Epub 2019 Feb 22.

Instituto Nacional de Câncer, Coordenação de Pesquisa, Rio de Janeiro, Rio de Janeiro, Brazil.

CAR T cell immunotherapy for the treatment of cancer is now an approved treatment for B-cell malignancies. However, the use of viral vectors to provide long-term CAR expression is associated with high production costs and cumbersome quality controls, impacting the final cost of CAR-T cell therapies. Non-viral integrative vectors such as Sleeping Beauty (SB) transposons provide an alternative to modify primary T cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/hum.2018.218DOI Listing
February 2019

Unusual findings of acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): A multicenter study.

Int J Lab Hematol 2019 Feb 22. Epub 2019 Feb 22.

Department of Hematology, School of Medicine, The Second Affiliated Hospital, Zhejiang University, Hangzhou, China.

Introduction: AML with inv(3)(q21.3q26.2) or t(3;3)(q21. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijlh.12987DOI Listing
February 2019

Ebp1 p48 promotes oncogenic activities in human colon cancer cells through regulation of TIF-90-mediated ribosomal RNA synthesis.

J Cell Physiol 2019 Feb 22. Epub 2019 Feb 22.

Department of Medical Biotechnology, Biotechnology Center of Ho Chi Minh City, Ho Chi Minh City, Vietnam.

The ErbB3-binding protein 1 (Ebp1) has been reported as either an oncogenic regulator or a tumor suppressor in a variety of cancers. Here, we show that Ebp1 p48, a predominant expression isoform, is highly expressed in the majority of human colon tumor cells compared with normal adjacent tissues and its expression is required for the oncogenic activities of these cells. Depletion of Ebp1 expression in primary colon cancer cells inhibits cell proliferation, colony forming, and invasion in vitro as well as tumor formation in vivo and enhances cell sensitivity to irradiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.28385DOI Listing
February 2019

Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor T-cell therapy.

Expert Rev Hematol 2019 Feb 22. Epub 2019 Feb 22.

a Division of Medical Oncology, Department of Internal Medicine , University of Washington School of Medicine , Seattle , WA , USA.

Introduction: Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated remarkable anti-tumor activity in B-cell malignancies and is under investigation in other hematologic malignancies and solid tumors. While highly efficacious, post-infusion T cell activity often results in massive cytokine release precipitating cytokine release syndrome (CRS), the signature toxicity of CAR T cells. This toxicity is characterized by systemic immune activation resulting in fever, hypotension, respiratory insufficiency and capillary leak. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1585238DOI Listing
February 2019

Establishment and molecular characterization of decitabine-resistant K562 cells.

J Cell Mol Med 2019 Feb 22. Epub 2019 Feb 22.

Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China.

The clinical activity of decitabine (5-aza-2-deoxycytidine, DAC), a hypomethylating agent, has been demonstrated in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. However, secondary resistance to this agent often occurs during treatment and leads to treatment failure. It is important to clarify the mechanisms underlying the resistance for improving the efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcmm.14221DOI Listing
February 2019

Current role of interferon in hairy cell leukemia therapy: a timely decision.

Hematol Transfus Cell Ther 2019 Jan-Mar;41(1):88-90. Epub 2018 Jun 11.

Instituto do Câncer do Estado de São Paulo (ICESP), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.htct.2018.04.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371201PMC

Revisiting the complete blood count and clinical findings at diagnosis of childhood acute lymphoblastic leukemia: 10-year experience at a single center.

Hematol Transfus Cell Ther 2019 Jan-Mar;41(1):57-61. Epub 2018 Jul 27.

Facultad de Medicina y Hospital Universitario, Universidad Autónoma de Nuevo León, Monterrey, Mexico.

Background: Heterogeneity regarding clinical and laboratory findings at diagnosis of acute lymphoblastic leukemia exists. The frequency of complete blood count abnormalities and its combinations, symptoms and physical findings were investigated in Hispanic children from an open population at the diagnosis of acute lymphoblastic leukemia.

Methods: The patient charts and electronic records of under 16-year-old children diagnosed with acute lymphoblastic leukemia over 10 years at a regional hematology center of a university hospital were analyzed to retrieve data concerning the complete blood count at first evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.htct.2018.05.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371227PMC

Role of physical function in predicting short-term treatment outcome in Egyptian acute myeloid leukemia patients: a single center experience.

Hematol Transfus Cell Ther 2019 Jan-Mar;41(1):17-24. Epub 2018 Jun 14.

Kasr Al-Ainy Hospital, Faculty of Medicine, Cairo University, Cairo, Egypt.

Background: Acute myeloid leukemia (AML) is a potentially fatal hematological disease. Along with disease-related factors, patient-related factors, in particular age, are a strong predictor of outcome that influence treatment decisions. Many acute myeloid leukemia risk stratification models have been developed to predict the outcome of intensive chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.htct.2018.05.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371199PMC

Assessing the impact of ABO incompatibility on major allogeneic hematopoietic stem cell transplant outcomes: a prospective, single-center, cohort study.

Hematol Transfus Cell Ther 2019 Jan-Mar;41(1):1-6. Epub 2018 Jul 10.

Hospital das Clínicas da Universidade Federal de Minas Gerais (HC UFMG), Belo Horizonte, MG, Brazil.

Background: ABO blood group incompatibility between donor and recipient is associated with a number of immunohematological complications, but is not considered a major contraindication to allogeneic hematopoietic stem cell transplantation. However, available evidence from the literature seems to be conflicting as to the impact of incompatibility on overall survival, event-free survival, transplant-related mortality, graft-versus-host disease, and time to neutrophil and platelet engraftment.

Methods: This single-center, prospective, cohort study included patients with hematological malignancies who underwent a first allogeneic hematopoietic stem cell transplantation between 2008 and 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.htct.2018.05.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371230PMC

The case of undiagnosed immunodeficiency in child from mother with leukemia anamnesis.

Interv Med Appl Sci 2018 Dec;10(4):216-221

Department of Pathology, Sumy State University, Sumy, Ukraine.

Acute lymphoblastic leukemia (ALL) in pregnant women is rare experience, but it can complicate the gestation by increasing the risk of miscarriage and premature birth. However, the adequate carrying of the pregnancy is possible for women who suffered from leukemia in childhood and achieved the remission during the treatment. Furthermore, there are some facts about the possibility of immunosuppression in children whose parents suffer from various immunodeficiency disorders, including ALL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1556/1646.10.2018.46DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376359PMC
December 2018

Inheritance of Susceptibility to Malignant Blood Disorders.

Sci Rep 2019 Feb 21;9(1):2444. Epub 2019 Feb 21.

Department of Hematology, Oslo University Hospital, KG Jebsen Center for B cell malignancies P.O. box 4950, Nydalen, NO 0424, Oslo, Norway.

Malignant blood disorders depend on heritable susceptibility genes and occur in familial aggregations. We suggest a model of transgenerational segregation of the susceptibility genes based on the study of malignant blood disorders in Norwegian and Danish families with unrelated parents, and in the inbred Faroese population with related parents. This model, consisting of parental genomic imprinting and mother-son microchimerism, can explain the male predominance in most of the diseases, the predominance of affected parent-offspring when parents are not related, and the different modes of segregation in males and females. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-38879-yDOI Listing
February 2019

TP53 immunohistochemistry correlates mutation status and clearance in decitabine-treated patients with myeloid malignancies.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

Dept. of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.205302DOI Listing
February 2019

Energy metabolism is co-determined by genetic variants in chronic lymphocytic leukemia and influences drug sensitivity.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

European Molecular Biology Laboratory (EMBL), Heidelberg, Germany;

Chronic lymphocytic leukemia cells have an altered energy metabolism compared to normal B cells. While there is growing understanding of the molecular heterogeneity of the disease, the extent of metabolic heterogeneity and its relation to molecular heterogeneity has not been systematically studied. Here, we assessed 11 bioenergetic features, primarily reflecting cell's oxidative phosphorylation and glycolytic activity, in leukemic cells from 140 chronic lymphocytic leukemia patients using metabolic flux analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.203067DOI Listing
February 2019

miR-101 suppresses the development of MLL-rearranged acute myeloid leukemia.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

Children Cancer Institute, University of New South Wales, Sydney, Australia;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.209437DOI Listing
February 2019

RUNX1 inhibits proliferation and induces apoptosis of t(8;21) leukemia cells via KLF4 mediated transactivation of P57.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and PUMC

RUNX1 is a key transcription factor in hematopoiesis and its disruption is one of the most common aberrations in acute myeloid leukemia. RUNX1 alterations affect its DNA binding capacity and transcriptional activities, leading to the deregulation of transcriptional targets and abnormality in proliferation and differentiation of myeloid cells. Identification of RUNX1 target genes and elucidation of their biological functions are of great importance to find new therapeutic strategies for RUNX1-altered leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.192773DOI Listing
February 2019

Bone marrow endothelial cell-derived interleukin-4 contributes to thrombocytopenia in acute myeloid leukemia.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital;

Normal hematopoiesis can be disrupted by the leukemic bone marrow microenvironment, which leads to cytopenia-associated symptoms including anemia, hemorrhage and infection. Among them, thrombocytopenia is a major and fatal complication in patients with acute leukemia. However, the mechanisms underlying defective thrombopoiesis in leukemia have not been fully elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.214593DOI Listing
February 2019

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

University of Virginia School of Medicine, Charlottesville, Virginia, USA.

CD20 monoclonal antibody therapies have significantly improved the outlook for patients with B-cell malignancies. However many patients acquire resistance, demonstrating the need for new and improved drugs. We previously demonstrated that the natural process of antibody hexamer formation on targeted cells allows for optimal induction of complement-dependent cytotoxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.207266DOI Listing
February 2019

Establishment and utility assessment of posterior reversible encephalopathy syndrome early warning scoring (PEWS) scale establishment and utility assessment of PEWS scale.

BMC Neurol 2019 Feb 21;19(1):30. Epub 2019 Feb 21.

Department of Pediatrics, Chinese PLA General Hospital, Beijing, 100853, People's Republic of China.

Background: Posterior reversible encephalopathy syndrome (PRES) is a complication that occurs during various diseases' treatment. Imaging examination is the gold standard for diagnosis. PRES frequently occurrence in patients with hematological malignancies results in poorer prognosis and higher mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12883-019-1247-0DOI Listing
February 2019

CRTAM NK cells endowed with suppressor properties arise in leukemic bone marrow.

J Leukoc Biol 2019 Feb 21. Epub 2019 Feb 21.

Unidad de Investigación Médica en Enfermedades Oncológicas, UMAE Hospital Oncología, Instituto Mexicano del Seguro Social, Mexico City, Mexico.

Due to their increasing rates of morbidity and mortality, childhood malignancies are considered a global health priority, with acute lymphoblastic leukemias (ALLs) showing the highest incidence worldwide. Control of malignant clone emergence and the subsequent normal-leukemic hematopoietic cell out-competition require antitumor monitoring mechanisms. Investigation of cancer surveillance innate cells may be critical to understand the mechanisms contributing in either disease progression or relapse, and to promote displacement of leukemic hematopoiesis by the normal counterpart. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/JLB.MA0618-231RDOI Listing
February 2019

Pretransplant HLA Typing Revealed Loss of Heterozygosity in the Major Histocompatibility Complex in a Patient with Acute Myeloid Leukemia.

Hum Immunol 2019 Feb 18. Epub 2019 Feb 18.

Indiana University School of Medicine, Department of Medicine, Division of Hematology and Oncology, Bone Marrow and Stem Cell Transplantation Program, Indiana University, Indianapolis, Indiana.

Introduction: Chromosomal abnormalities are frequent events in hematological malignancies. The degree of HLA compatibility between donor and recipient in hematopoietic stem cell transplantation is critical.

Purpose Of The Study: In this report, we describe an acute myeloid leukemia case with loss of heterozygosity (LOH) encompassing the entire HLA. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01988859183120
Publisher Site
http://dx.doi.org/10.1016/j.humimm.2019.02.009DOI Listing
February 2019
1 Read

Concise Review: Regulation of Self-Renewal in Normal and Malignant Hematopoietic Stem Cells by Krüppel-Like Factor 4.

Stem Cells Transl Med 2019 Feb 21. Epub 2019 Feb 21.

Department Pathology & Immunology, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.

Pluripotent and tissue-specific stem cells, such as blood-forming stem cells, are maintained through a balance of quiescence, self-renewal, and differentiation. Self-renewal is a specialized cell division that generates daughter cells with the same features as the parental stem cell. Although many factors are involved in the regulation of self-renewal, perhaps the most well-known factors are members of the Krüppel-like factor (KLF) family, especially KLF4, because of the landmark discovery that this protein is required to reprogram somatic cells into induced pluripotent stem cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/sctm.18-0249DOI Listing
February 2019

A near-haploid clone harboring a BCR/ABL1 gene fusion in an adult patient with newly diagnosed B-lymphoblastic leukemia.

Genes Chromosomes Cancer 2019 Feb 20. Epub 2019 Feb 20.

Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

The detection of recurrent genetic abnormalities in B-lymphoblastic leukemia (B-ALL) is critical for risk stratification and therapy-related decisions. Near-haploidy (24-30 chromosomes), a subgroup of hypodiploidy (<46 chromosomes), and BCR/ABL1 gene fusions are both recurrent genetic abnormalities in B-ALL and are considered adverse prognostic findings, although outcomes in BCR/ABL1-positive patients have improved with tyrosine kinase inhibitor therapy. While near-haploid clones are primarily observed in children and rarely harbor structural abnormalities, BCR/ABL1-positive B-ALL is primarily observed in adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22744DOI Listing
February 2019

Hyperammonemia From Ureaplasma Infection in an Immunocompromised Child.

J Pediatr Hematol Oncol 2019 Feb 15. Epub 2019 Feb 15.

Miller Children's and Women's Hospital Long Beach.

Idiopathic hyperammonemia is a rare, poorly understood, and often lethal condition that has been described in immunocompromised patients. This report describes an immunocompromised patient with acute myelogenous leukemia who developed persistent hyperammonemia up to 705 µmol/L (normal, 0 to 47 µmol/L) refractory to multiple different therapies. However, after beginning azithromycin and then doxycycline therapy for Ureaplasma species infection, the patient showed immediate and sustained clinical improvement and resolution of ammonia levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001414DOI Listing
February 2019

Propagation and Maintenance of Mouse Embryonic Stem Cells.

Methods Mol Biol 2019 ;1940:33-45

Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia.

Mouse embryonic stem cells (mESCs) are pluripotent cells derived from preimplantation embryos that have the capacity to self-renew indefinitely in vitro. mESCs are an indispensable tool for studying cellular differentiation in vitro, generating disease in a dish models, and have been used extensively for the generation of transgenic animals. Therefore, maintaining their pluripotent state, even after extended culture, is crucial for their utility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9086-3_3DOI Listing
January 2019

Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis.

Int J Hematol 2019 Feb 20. Epub 2019 Feb 20.

Department of Hematology, Ome Municipal General Hospital, 4-16-5, Higashiome, Ome, Tokyo, Japan.

A 64-year-old man was diagnosed with limited cutaneous systemic sclerosis 5 years prior to this report. His sclerotic skin symptoms did not respond to oral low-dose prednisone (5-10 mg/day). Five years after the diagnosis, the patient presented with leukocytosis 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-019-02618-wDOI Listing
February 2019

Immunochemotherapy for Richter syndrome: current insights.

Immunotargets Ther 2019 5;8:1-14. Epub 2019 Feb 5.

Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland,

Richter syndrome (RS) is recognized as the development of a secondary and aggressive lymphoma during the clinical course of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Most of such histological transformations are from RS to diffuse large B-cell lymphoma (DLBCL-RS, 90%) and Hodgkin's lymphoma (HL-RS, 10%). Histopathological examination is a prerequisite for diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/ITT.S167456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368420PMC
February 2019

Highly efficient novel recombinant L-asparaginase with no glutaminase activity from a new halo-thermotolerant strain.

Bioimpacts 2019 13;9(1):15-23. Epub 2018 Sep 13.

Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

The bacterial enzyme has gained more attention in therapeutic application because of the higher substrate specificity and longer half-life. L-asparaginase is an important enzyme with known antineoplastic effect against acute lymphoblastic leukemia (ALL). Novel L-asparaginase genes were identified from a locally isolated halo-thermotolerant strain and the recombinant enzymes were overexpressed in modified strains, Origami B and BL21. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15171/bi.2019.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378094PMC
September 2018

Investigation of the changes in the expression levels of gene in colorectal cancer tissues.

J Gastrointest Oncol 2019 Feb;10(1):68-73

Liver and Gastroenterology Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Background: MOZ is one of the most important histone acetyltransferases (HATs) that has an effective role in gene expression. It is an important partner in chromosomal rearrangement that usually occurs in hematological malignancies such as leukemia. Besides these malignancies, its role in solid tumors has been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jgo.2018.09.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351307PMC
February 2019

'Acute leukemia in congenital methehemoglobinemia - an enigma to explore'.

J Community Hosp Intern Med Perspect 2019 6;9(1):55-58. Epub 2018 Dec 6.

Department of Internal Medicine, University of Nevada, Reno, NV, USA.

Congenital methemoglobinemia is a rare disease, resulting in increased oxygen affinity and impaired oxygen delivery to the tissues. While there have been studies that have linked acquired methemoglobinemia in almost 79% of leukemia patients, to the best of our knowledge, this is the first case of leukemia development in a patient with congenital methemoglobinemia. Chronic deprivation of oxygen to metabolically active bone marrow can theoretically lead to hematopoietic disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/20009666.2018.1555431DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374924PMC
December 2018

Ibrutinib-induced cardiomyopathy.

J Community Hosp Intern Med Perspect 2019 11;9(1):50-52. Epub 2019 Feb 11.

Hematology/Oncology Department, Baylor College of Medicine, Houston, TX, USA.

The use of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies is blooming. Atrial fibrillation is a known side effect of ibrutinib but cardiomyopathy was not reported previously. We present an 88-year-old man with CLL who was admitted to the hospital with new-onset atrial fibrillation and symptomatic systolic congestive heart failure one month after ibrutinib initiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/20009666.2018.1555432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374917PMC
February 2019

Adult Burkitt lymphoma- an Island between lymphomas and leukemias.

J Community Hosp Intern Med Perspect 2019 11;9(1):25-28. Epub 2019 Feb 11.

Department of Internal Medicine, Hackensack Meridian Health- Ocean Medical Centre, Brick, NJ, USA.

: Burkitt lymphoma is a rare, aggressive and rapidly fatal, B-cell non-Hodgkin's lymphoma. It has an incidence of 0.4/100,000 age-adjusted to the USA standard population. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/20009666.2019.1
Publisher Site
http://dx.doi.org/10.1080/20009666.2019.1574545DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374956PMC
February 2019
1 Read

NVP-BEZ235-induced autophagy as a potential therapeutic approach for multiple myeloma.

Am J Transl Res 2019 15;11(1):87-105. Epub 2019 Jan 15.

Department of Hematology, Nanfang Hospital, Southern Medical University Guangzhou 510010, China.

Background: The PI3K/Akt/mTOR pathway is constitutively activated in human multiple myeloma (MM) cell lines and in freshly isolated plasmocytes from patients with MM. The mTOR signaling pathway has been designated an attractive anti-tumor target in multiple myeloma. NVP-BEZ235, a novel, dual class I PI3K/mTOR inhibitor, is an imidazoquinoline derivative. Read More

View Article

Download full-text PDF

Source
January 2019

Molecular Players in Hematologic Tumor Cell Trafficking.

Front Immunol 2019 6;10:156. Epub 2019 Feb 6.

Department of Molecular Biomedicine, Centro de Investigaciones Biológicas (CSIC), Madrid, Spain.

The trafficking of neoplastic cells represents a key process that contributes to progression of hematologic malignancies. Diapedesis of neoplastic cells across endothelium and perivascular cells is facilitated by adhesion molecules and chemokines, which act in concert to tightly regulate directional motility. Intravital microscopy provides spatio-temporal views of neoplastic cell trafficking, and is crucial for testing and developing therapies against hematologic cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372527PMC
February 2019

Whole-Genome Sequences of Five Strains From a Child With Leukemia M2.

Front Microbiol 2019 6;10:132. Epub 2019 Feb 6.

Laboratorio de Investigación en Bacteriología Intestinal, Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

is an opportunistic pathogen and is one of the primary etiological agents of healthcare-associated infections (HAIs). infections are difficult to treat due to the intrinsic and acquired antibiotic resistance of strains of this bacterium, which frequently limits therapeutic options. In this study, five strains (810CP, 433H, 434H, 483H, and A-2), all of which were isolated from a child with leukemia M2, were characterized through antibiotic susceptibility profiling, the detection of genes encoding carbapenem hydrolyzing oxacillinases, pulsed-field gel electrophoresis (PFGE), multilocus sequence typing (MLST), adherence and invasion assays toward the A549 cell line, and the whole-genome sequence (WGS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmicb.2019.00132DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372515PMC
February 2019

Correction: Bone marrow MSCs in MDS: contribution towards dysfunctional hematopoiesis and potential targets for disease response to hypomethylating therapy.

Leukemia 2019 Feb 20. Epub 2019 Feb 20.

Department of Hematology, Singapore General Hospital, Singapore, Singapore.

In the original version of this article there was a mistake in the spelling of the author Sujoy Ghosh, originally spelt Sujoy Gosh. This has now been corrected in both the PDF and HTML versions of the article. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0406-zDOI Listing
February 2019

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.

Leukemia 2019 Feb 20. Epub 2019 Feb 20.

Cellular Signalling Laboratory, Human Anatomy Section, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations analyses were performed at baseline and during the therapy. Results were then correlated to clinical outcome, overall survival (OS), leukemia-free-survival (LFS) and response to therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0416-xDOI Listing
February 2019

Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.

Leukemia 2019 Feb 20. Epub 2019 Feb 20.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma (SMM), or solitary plasmacytoma (SPC). There is a lack of data regarding impact of these pre-existing monoclonal gammopathies (MGs) on MM outcomes. Patients with prior diagnosis of MGUS, SMM, or PC from 1973 to 2015 (cases) were identified from our institution's database and compared to those without a known MG (controls). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0419-7DOI Listing
February 2019

Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients.

Sci Rep 2019 Feb 20;9(1):2412. Epub 2019 Feb 20.

Department of Biotechnology, Sri Venkateswara Institute of Medical Sciences, Tirupati, 517507, Andhra Pradesh, India.

Mutations in the drug binding region of BCR-ABL lead to imatinib resistance during the management of chronic myeloid leukemia (CML). In our study, 62 Philadelphia positive (Ph) CML patients showing conspicuous expression of BCR-ABL gene were treated with imatinib. At the end of 3 months, 21/62 (33. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-38672-xDOI Listing
February 2019

Histone H1 quantity determines the efficiencies of apoptotic DNA fragmentation and chromatin condensation.

Biomed Res 2019 ;40(1):51-56

Research Institute for Biomedical Sciences, Tokyo University of Science.

Oligonucleosomal DNA fragmentation and chromatin condensation are two hallmarks of apoptosis. However, their generation mechanisms are not entirely understood. Histone H1, a positively charged nuclear protein located in the linker region of chromatin, is involved in higher-order chromatin structures and tight chromatin packing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2220/biomedres.40.51DOI Listing
January 2019

Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide.

J Immunol 2019 Feb 20. Epub 2019 Feb 20.

Etablissement Français du Sang, 44011 Nantes Cedex 01, France.

Little is known regarding the effect of KIR/HLA incompatibilities (inc.) in the setting of T-replete haploidentical allogeneic hematopoietic stem cell transplantation using posttransplant cyclophosphamide (PTCy). In this retrospective study, the impact of KIR/HLA inc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1801489DOI Listing
February 2019

Cells of adult T-cell leukemia evade HTLV-1 Tax/NF-κB hyperactivation-induced senescence.

Blood Adv 2019 Feb;3(4):564-569

Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD.

Human T-cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T-cell leukemia/lymphoma (ATL). The HTLV-1 viral -activator/oncoprotein Tax is a major driver of ATL, yet it induces rapid p21 (p21)- and p27-mediated cellular senescence through constitutive activation (hyperactivation) of NF-κB. Although constitutive NF-κB activation is a common feature of T/B-cell leukemia/lymphoma, including ATL, it is not known how ATL cells maintain chronic NF-κB activation without undergoing senescence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018029322DOI Listing
February 2019

Fear and coping in children 5-9 years old treated for acute lymphoblastic leukemia - A longitudinal interview study.

J Pediatr Nurs 2019 Feb 17. Epub 2019 Feb 17.

Faculty of Health, Science and Technology, Institution for Health, Karlstad University, Karlstad, Sweden; University Health Care Research Center, School of Health and Medical Sciences, Örebro University, Örebro, Sweden. Electronic address:

Purpose: The aim of this study was to describe the fears of 5- to 9-year-old children related to having acute lymphoblastic leukemia (ALL) and their strategies for coping with those fears.

Design And Methods: The study had a qualitative descriptive longitudinal design and included a total of 35 interviews with 13 children at three different times during their treatment period. Data were analyzed using a matrix-based method inspired by the work of Miles et al. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pedn.2019.02.007DOI Listing
February 2019

Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review.

Immunotherapy 2019 Apr;11(5):373-378

Department of Hematology, Taussig Cancer Center, Medical Oncology, Cleveland Clinic, Cleveland, OH 44195, USA.

Blinatumomab and donor lymphocyte infusion (DLI) combination is a promising cancer therapy, whereby blinatumomab might achieve an initial reduction in leukemic-cell burden using T cells, and after tumor clearance, DLI can potentially stimulate the donor immune system to achieve longer lasting remission. Here, we present a 51-year-old female with mixed phenotype acute leukemia who had a hematologic relapse 3 months after she received total body irradiation-based myeloablative allogeneic hematopoietic stem cell transplantation from an unrelated human leukocyte antigen matched (10/10) donor and achieved complete remission with minimal residual disease negativity by multi-parameter flow cytometry using the combination of blinatumomab and DLI. To the best of our knowledge, this is the first report to describe the use of blinatumomab and DLI combination therapy in the treatment of B/myeloid mixed phenotype acute leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0104DOI Listing